Oncolytics Biotech Inc T.ONC

The Karolinska Institutet develops predictive diagnostic

[Noteable]

December 27, 2022 - On the heels of ONCY's AWARE-1 biomarker work involving the development of a predictive diagnostic for the treatment of breast cancer, researchers at Karolinska Institutet in Sweden have developed a method that should be able to predict whether a patient with breast cancer will benefit from a particular treatment or not. The cell-based method has been tested on patients with promising results, according to a study published in PNAS. 

From biopsies taken before surgery, the researchers created tumour models for each patient and exposed them to the same drugs the patient received. Thereafter, the drug sensitivity of the models was compared with the patients' treatment response. 

The results show that the treatment responses predicted by the tumour model were broadly consistent with the treatment responses the patient subsequently exhibited. For example, the model predicted the treatment response from the chemotherapy drug epirubicin with 90 percent accuracy, while four of four patients treated and tested for anti-HER2 monoclonal antibody drugs showed consistency.

 

https://www.news-medical.net/news/20221227/Cell-based-method-can-predict-how-breast-cancer-patients-will-respond-to-treatments.aspx